Abstract
To evaluate the effects of gut metabolism and efflux on drug absorption by simulation studies using a pharmacokinetic model involving diffusion in epithelial cells. A pharmacokinetic model for drug absorption was constructed including metabolism by CYP3A4 inside the epithelial cells, P-gp-mediated efflux into the lumen, intracellular diffusion from the luminal side to the basal side, and subsequent permeation through the basal membrane. Partial differential equations were solved to yield an equation for the fraction absorbed from gut to the blood. Effects of inhibition of CYP3A4 and/or P-gp on the fraction absorbed were simulated for a hypothetical substrate for both CYP3A4 and P-gp. The fraction absorbed after oral administration was shown to increase following inhibition of P-gp. This increase was more marked when the efflux clearance of the drug was greater than the sum of the metabolic and absorption clearances and when the intracellular diffusion constant was small. Furthermore, it was demonstrated that the fraction absorbed was synergistically elevated by simultaneous inhibition of both CYP3A4 and P-gp. The analysis using our present diffusion model is expected to allow the prediction of in vivo intestinal drug absorption and related drug interactions from in vitro studies using human intestinal microsomes, gut epithelial cells, CYP3A4-expressed Caco-2 cells, etc.
MeSH Terms
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism
Absorption
Computer Simulation
Cytochrome P-450 CYP3A
Cytochrome P-450 Enzyme System/metabolism
Epithelial Cells/metabolism
Humans
Intestines/enzymology
Mixed Function Oxygenases/metabolism
Models, Biological
Pharmaceutical Preparations/metabolism
Pharmacokinetics
Chemicals
ATP Binding Cassette Transporter, Subfamily B, Member 1
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Mixed Function Oxygenases
CYP3A protein, human
Cytochrome P-450 CYP3A
CYP3A4 protein, human
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Ito K
School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
Kusuhara H
Sugiyama Y
References (29)
29 references, click to expand
-
Physiological measurements of luminal stirring in the dog and human small bowel.
J Clin Invest. 1990 Nov;86(5):1540-7
PMID: 2243130
-
Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.
Pharmacol Rev. 1998 Sep;50(3):387-412
PMID: 9755288
-
Construction of a physiologically based pharmacokinetic model to describe the hepatobiliary excretion process of ligands: quantitative estimation of intracellular diffusion.
Biol Pharm Bull. 1993 Mar;16(3):273-9
PMID: 8364472
-
Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.
Biochem Biophys Res Commun. 1991 Mar 29;175(3):880-5
PMID: 1673839
-
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
J Clin Invest. 1992 Nov;90(5):1871-8
PMID: 1430211
-
Cyclosporin-erythromycin interaction in renal transplant patients.
Br J Clin Pharmacol. 1989 Apr;27(4):475-81
PMID: 2655690
-
Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine.
Pharm Res. 1995 Sep;12(9):1304-10
PMID: 8570526
-
A quantitative study of fluorescein isothiocyanate-dextran transport in the microcirculation of the isolated perfused rat liver.
Hepatology. 1989 Jan;9(1):75-82
PMID: 2461894
-
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
Clin Pharmacol Ther. 1997 Sep;62(3):248-60
PMID: 9333100
-
Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3.
Mol Pharmacol. 1997 May;51(5):741-54
PMID: 9145912
-
Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4.
Pharm Res. 1996 Nov;13(11):1635-41
PMID: 8956327
-
Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics.
Biopharm Drug Dispos. 1996 May;17(4):273-310
PMID: 8845471
-
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.
Mol Carcinog. 1995 Jul;13(3):129-34
PMID: 7619215
-
Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.
Pharmacol Ther. 1997;73(2):147-71
PMID: 9131722
-
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine.
Clin Pharmacol Ther. 1995 Jul;58(1):15-9
PMID: 7628178
-
Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport.
Annu Rev Pharmacol Toxicol. 1998;38:461-99
PMID: 9597163
-
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Clin Pharmacol Ther. 1996 May;59(5):491-502
PMID: 8646820
-
Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues.
J Pharmacol Exp Ther. 1990 Apr;253(1):387-94
PMID: 2329521
-
Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine.
Clin Pharmacol Ther. 1995 Nov;58(5):492-7
PMID: 7586942
-
How crowded is the cytoplasm?
Cell. 1982 Sep;30(2):345-7
PMID: 6754085
-
Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier.
J Pharm Pharmacol. 1996 Oct;48(10):1083-9
PMID: 8953513
-
Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
Drug Metab Dispos. 1998 Apr;26(4):360-6
PMID: 9531525
-
First-pass metabolism of cyclosporin by the gut.
Lancet. 1991 Dec 14;338(8781):1488-90
PMID: 1683920
-
Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
J Pharmacol Exp Ther. 1997 Dec;283(3):1552-62
PMID: 9400033
-
Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption.
Pharm Res. 1997 Apr;14(4):486-91
PMID: 9144736
-
Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction.
Clin Pharmacol Ther. 1992 Nov;52(5):453-7
PMID: 1424418
-
Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration.
J Toxicol Sci. 1996 Dec;21(5):309-16
PMID: 9035043
-
Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
Mol Pharmacol. 1996 Feb;49(2):311-8
PMID: 8632764
-
Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A.
Biochem Pharmacol. 1997 Apr 25;53(8):1187-95
PMID: 9175724